SCHEMBL8221845

SCHEMBL8221845

Nc1nc2ccccc2c2nn(Cc3ccc(Cl)cc3)c(=O)n12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 15/20 0.55
▸ TNF P01375 1/20 0.50
▸ CXCL8 P10145 1/20 0.50
▸ SOS1 Q07889 1/20 0.50
▸ NOD2 Q9HC29 1/20 0.50
▸ NOD1 Q9Y239 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ ADORA1 P30542 2/20 0.48
▸ LMNA P02545 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ APP P05067 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8221822 0.92 ADORA2A (0.63) ADORA2AALDH1A1SMN1; SMN2ADORA1LMNA
SCHEMBL8223871 0.91 ADORA2A (0.53) ADORA2AADORA1
SCHEMBL8217493 0.89 ADORA2A (0.54) ADORA2AADORA1APP
SCHEMBL13341606 0.89 KMT2A (0.54) ADORA2AADORA1CYP2C9
SCHEMBL8223855 0.89 ADORA2A (0.64) ADORA2AADORA1APP
SCHEMBL8224064 0.88 ADORA2A (0.49) ADORA2ASOS1ADORA1
SCHEMBL8221514 0.87 ADORA2A (0.57) ADORA2AADORA1
SCHEMBL8225409 0.86 ADORA2A (0.52) ADORA2AADORA1APP
SCHEMBL8223331 0.86 ADORA2A (0.49) ADORA2AADORA1
SCHEMBL8221499 0.85 NPSR1 (0.48) ADORA2ATNFNOD2NOD1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713985-B2 Adenosine Aa2 receptor antagonists SCHERING CORPORATION (US) 2010-05-11 — — US disclosed
US-7713985-B2 Adenosine Aa2 receptor antagonists SCHERING CORPORATION (US) 2010-05-11 — — US disclosed
EP-2038285-B1 ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORP (US) 2010-02-17 — — EP disclosed
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2008-10-16 — — US disclosed
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2008-10-16 — — US disclosed
WO-2008002596-A2 ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS ADORA3, ADORA2A, ADORA1 ADORA2A 2/4885TNF 4494/4885CXCL8 2154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback